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Atrial fibrillation (AF) is the most widely recognized arrhythmia. Systemic arterial hypertension, diabetes, obesity, heart failure,
and valvular heart diseases are major risk factors for the onset and progression of AF. Various studies have emphasized the
augmented anxiety rate among AF patients due to the poor quality of life; however, little information is known about the
possibility of triggering atrial fibrillation by anxiety. +e present review sought to underline the possible pathophysiological
association between AF and anxiety disorders and suggests that anxiety can be an independent risk factor for AF, acting as a
trigger, creating an arrhythmogenic substrate, andmodulating the autonomic nervous system.+e awareness of the role of anxiety
disorders as a risk factor for AF may lead to the development of new clinical strategies for the management of AF.
1. Introduction
Atrial fibrillation (AF) is the most common arrhythmia in
clinical practice, with an overall prevalence of 1-2% in the
general population [1] and an incidence that increases with
age up to 20% in octogenarians. In the next 50 years, its
prevalence is expected to double, as a consequence of the
prolongation of life expectancy [2]. Five types of AF are
classified: first diagnosed, paroxysmal, persistent, long-
standing persistent, and permanent AF (KirchhoffAF and
psychological factors). AF is associated with high relative
risk of all-cause mortality, stroke, cardiovascular mortality,
cardiac events, heart failure, and chronic cognitive im-
pairment and represents the most common arrhythmia that
requires hospitalization and one of the most frequent causes
of hospitalization for heart diseases. Several risk factors and
heart diseases are known to be involved in the genesis and/or
perpetuation of AF, acting by different pathophysiological
pathways on the presence of a susceptible atrial electro-
anatomic substrate. Among risk factors [3], both
unmodifiable, as genetic susceptibility, age, gender, race, and
modifiable, as systemic arterial hypertension, diabetes
mellitus, smoking, obstructive sleep apnea, and obesity, have
adverse effects on cardiovascular hemodynamic as well as on
cardiac structure and function, increasing the prevalence of
AF. Moreover, heart failure (HF) and AF frequently coexist:
HF predisposes AF and vice versa. Left ventricular dys-
function, independently from ejection fraction, is linked to
AF by a hemodynamic overload [4]; on the other hand, as
well known, AF can decrease overall cardiac output from
loss of atrial kick [5].
Over the last decades, epidemiological studies associated
various risk factors with AF. Moreover, many reports have
advanced the hypothesis of a mutual relationship between
AF and anxiety disorders, in which the latter can pave a
background that is favourable for the initiation and pro-
gression of the former. Anxiety is generally defined as a
psychobiological emotional state or reaction that consists of
unpleasant feelings of tension, apprehension, nervousness,
worry, and activation of the autonomic nervous system [6].
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+e diagnosis of anxiety includes specific phobia, social
phobia, panic disorder, agoraphobia, and generalized anx-
iety disorder [7]. Traditionally, anxiety has been considered a
consequence of AF due to the impairment in quality of life
associated with this arrhythmia. While it is well known that
anxiety is an independent risk factor for cardiovascular
disease, associated with a 26% increased risk of incident
coronary heart disease (CHD) and a 48% increased risk of
cardiac death [8–10], less is known about the role of anxiety
disorders in AF onset, severity, and clinical outcomes. +e
recognition of the involvement of such psychological factors
in the development of AF may help the identification of new
clinical strategies for the management of AF.
2. Pathophysiological Insights for the
Link between AF and Anxiety Disorders
+e onset and progression of AF is the result of the in-
teraction between three elements that form Coumel’s tri-
angle of arrhythmogenesis: the arrhythmogenic substrate,
the trigger factors, and the modulation factors, of which the
most common is the autonomic nervous system.
Several studies show a possible association of anxiety
disorders and AF. Nevertheless, a clear relationship has
never been demonstrated, this association should be based
on the pathophysiological consequences of the anxious state
on the neuroendocrine, coagulative, microcirculatory, and
immune systems.
It is known that inflammation and oxidative stress are
key players for the development of AF through atrial fibrosis,
myocyte apoptosis and/or necrosis, and irregular myocel-
lular hypertrophy with disarrangement of lines of cells and
recruitment of macrophages to the endothelial surface [11].
All these factors constitute the anatomical arrhythmogenic
substrate that results in shortening and dispersion of re-
fractory period, conduction velocity slowing, and formation
of reentry circuits. +e arrhythmogenic substrate resulting
from anatomical and electrophysiological atrial remodelling
predisposes to onset and maintenance of AF.
+e relationship between inflammatory cytokines and
AF risk has been previously described in multiple setting,
and both C-reactive protein and interleukin-6 are in-
dependently associated with AF [12–15]. Many studies
showed that anxiety and depressive disorders are linked to
low-grade systemic inflammation [12, 16–18]. For example,
the ATTICA study evaluated various inflammation and
coagulation markers among healthy adults in relation to the
anxious state (assessed by Spielberger’s State-Trait Anxiety
Inventory, STAI). STAI score was positively correlated with
C-reactive protein, interleukin-6, homocysteine, and fi-
brinogen levels. +e ATTICA study provided strong evi-
dence that anxiety is associated with systemic inflammation
and abnormal coagulation process, possibly leading to in-
creased cardiovascular events [6].
Moreover, stress response has been described as
resulting from a “fight or flight” reaction that can be the
result of endocrine, nervous, and immune systems [18].
+e inflammatory state found in anxious and depressive
disorders is presumably related to a hyperactivity of the
hypothalamic-pituitary-adrenal (HPA) axis which is com-
monly seen in patients with chronic stress. Although the
HPA axis in normal situations should temper inflammatory
reactions, prolonged hyperactivity of the HPA axis might
result in blunted anti-inflammatory responses to gluco-
corticoids resulting in increased inflammation [16, 19, 20]
Furthermore, hyperactivity of the HPA axis with cortisol
hyperproduction and corticotropin-releasing hormone
(CRH) overdrive produces an imbalance of monoamines; in
particular, chronic stress leads to a reduced activity of do-
paminergic, serotoninergic, and noradrenergic neurons [18].
In fact, persisting hypercortisolemia decreases serotonin
production. For this reason, antidepressants act on mono-
amines replacement as well as on modulation of cerebral
glucocorticoid receptors [21, 22].
Additionally, patients suffering from anxious and de-
pressive disorders are more likely to have increased activity
of sympathetic nervous system [23] and subsequently cat-
echolamine overload [24, 25]. It is known that elevated
serum catecholamine levels can trigger Takotsubo (or stress)
cardiomyopathy through microvascular endothelial damage
and catecholamine cardiotoxic effects [26, 27]. On the other
hand, acute emotional stress and chronic anxiety disorders
are considered predisposing risk factors for stress cardio-
myopathy because of the higher prevalence of these psy-
chosocial factors than that in the acute coronary syndrome
patients as well as in general population [28, 29]. In anxiety
disorders, serum catecholamine levels are elevated; thus, the
susceptibility to AF may be in part related to anxiety dis-
orders through the same catecholamine-mediated myocar-
dial injury seen in stress cardiomyopathy. Catecholamine
overload in anxiety disorders could lead to the formation of
the arrhythmogenic substrate and could be a trigger for the
onset of paroxysmal AF. +e morphological alterations
caused by catecholamine overload include: extracellular
matrix overproduction, contraction band necrosis, and
mononuclear cell infiltration [26, 27]. Catecholamine
overload leads to an extracellular accumulation of collagen
alfa-1 (I) chain and to an increased ratio of collagen alfa-1 (I)
chain to collagen alfa-1 (III) chain that results in a large and
rapid increase in atrial fibrosis [27]. +e increased release of
catecholamines results in an enhanced catecholamine deg-
radation, which in turn leads to production of reactive
oxygen species [30, 31], and in increased level of profibrotic
mediator like angiotensin II, TGF beta, and osteopontin
[32]. On the other hand, matrix metalloproteinase are not
correspondingly activated with the result of augmentation of
extracellular matrix proteins, myocardial disarray, and
negative atrial remodelling. Lastly, the overstimulation of
beta-adrenoreceptors by supraphysiologic levels of cat-
echolamines alters the expression of calcium-regulatory
protein genes [33, 34]. +e impairment of the calcium-
handling system causes ultrastructural atrial remodelling
and predisposes to the onset and progression of AF. Anxiety
disorders can trigger AF through the increased activity of
sympathetic nervous system that is known to be the most
important modulation factor of Coumel’s triangle of
arrhythmogenesis. Patients with anxiety have reduced heart
rate variability and vagal tone [35], which suggests an
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abnormal autonomic system regulation and represents an
independent risk factor for AF [36].
Lastly, individuals who suffer from anxiety have a
stimulated renin-angiotensin-aldosterone system (RAAS)
[37]. Elevated levels of angiotensin II stimulate mitogen-
activated protein kinases and reduce collagenase activity,
which results in cardiac fibrosis and left ventricular hy-
pertrophy. Binding of angiotensin II to angiotensin II type I
receptors induces transforming growth factor-1 (TGF-1)
production which promotes atrial fibrosis [27]. +us, the
hyperactivity of RAAS results in detrimental cardiac
remodelling with abnormal ventricle relaxation, diastolic
impairment, and increased atrial pressure and stretch. All
these mechanisms can promote AF by slowing atrial con-
duction velocity and providing a greater atrial surface for
reentry.
3. Discussion
As mentioned above, chronic stress and anxious state can
promote AF through several mechanisms acting at different
levels as trigger, modulating the autonomic nervous system
and modifying the atrial substrate. In sum, anxiety disorders
can interact with all the three elements of the triangle of
Coumel resulting in the arrhythmogenesis of AF.
We are underlying the possible pathophysiological
consequences of the chronic stress and anxious state on the
neuroendocrine, coagulative, microcirculatory, and immune
systems; however, a strict relationship between AF and
anxiety has never been demonstrated so far. Nevertheless,
several studies clearly show the strong association of anxiety
symptoms and onset or recurrence of AF strengthening the
hypothesis of the existence of causal link between these two
disorders.
For example, Eaker et al. showed that anxiety is a risk
factor for incident AF in males and females over a 10-year
time period [38, 39]. Moreover, it has been reported that
anxiety symptoms increased the incidence of AF after
cardiac surgery and the use of beta-blockers may reduce this
correlation [40, 41].
Increased sympathetic tone, lessened vagal tone, and the
cardinal symptoms of anxiety could be major provocative
factors of postoperative AF acting as trigger and modulating
the autonomic nervous system [24, 40].
Additionally, Lange and Herrmann-Lingen [42] found
that after successful electrical cardioversion, risk of re-
currence of AF remains existent due to anxiety. For those AF
patients who scored more than 7 on Hospital Anxiety and
Depression Scale (HADS), 85% have the possibility of re-
currence. In another study, Yu et al. reported an increased
risk of AF recurrence due to anxiety after taking circum-
ferential pulmonary vein ablation [24, 43]. +ese studies
show that anxiety disorders have an impact on AF treatment
success, suggesting that these psychological disturbances can
have a major role on the development and progression of
AF.
+ere is a small study which found that paroxetine re-
duces drug-resistant paroxysmal AF, presumably modu-
lating vagal tone at the level of the midbrain and inhibiting
the vasovagal reflex [9, 44]. In the last decades, a bulk of data
demonstrated the efficacy of selective serotonin reuptake
inhibitors (SSRIs) and serotonin and norepinephrine
reuptake inhibitors (SNRIs) in anxiety disorders [45]. +ese
studies may suggest the usefulness of SSRIs and SNRIs in
patients with AF and anxiety disorders. Pragmatic ran-
domized controlled trials with antidepressants are needed to
explore a possible effect on the course of AF in patients with
comorbid psychosocial disorders.
All these evidences suggest that anxious disorders may
create an environment that is favourable of the initiation and
perpetuation of AF [9]. Nevertheless, the above-mentioned
studies have several limitations as such as the small sample
size, the short follow-up period, and they are single-center
experiences using different questionnaires with heteroge-
neous validity and reliability. Additionally, the rating scales
used in epidemiological studies, as Eaker’s one, are not
necessarily the same scales used to diagnose anxiety dis-
orders in daily clinical practice. +ese findings suggest that
future research should involve large multicentre prospective
trials, with long follow-up period using thorough, exhaus-
tive, and homogeneous interviews and scales for the di-
agnoses of anxiety disorders.
+e identification of anxiety disorders as independent
risk factor for AF opens new scenarios in the management of
this arrhythmia.
Firstly, in patients with multiple risk factors for AF,
anxiety assessment should be routinely performed through
standardized questionnaire, as the Hamilton Anxiety Rating
Scale (HAM-A) [46], Spielberger’s State Anxiety Inventory
(STAI) [47], and the Zung Self-Rating Anxiety Scale (SAS)
[48], to identify this psychosocial risk factor and possibly
prevent AF onset and progression. Moreover, in this setting,
it is important to underline the need of a clinical diagnosis of
anxiety disorders in order to make a differential diagnosis
with depressive disorders that might also be present as
comorbidity.
Secondly, it might be interesting to evaluate whatever
identification and treatment of anxious states could be useful
to improve outcomes and optimize the management of this
arrhythmia in patients with recurrent AF, or treatment-
resistance AF.
Lastly, future prospective well-designed studies should
clarify the possible causal role of anxiety disorders in the
onset of AF in patients after surgery. Considering the
possible causal link between AF and anxiety in patients after
cardiac surgery, the usefulness of beta-blockers, benzodi-
azepines, and SSRI should be evaluated in reducing the
incidence and in the management of postoperative AF.
4. Conclusions
+e present review underlines the possible pathophysio-
logical mechanisms through which anxiety disorders can
promote the onset, progression, and maintenance of AF. A
relationship may exist between the most common clinical
arrhythmia and anxious states. +e recognition of the in-
volvement of such psychological factors in the development
of AF may help the identification of new clinical strategies
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for the management of AF. Nevertheless, a few studies
pointed out the possible role of psychological factors on the
development of AF, and a clear association has not been
demonstrated yet. Considering the limitations of the present
studies addressing a role of anxiety disorders as risk factor
for AF and the high health burden of AF, large prospective
studies are necessary to elucidate this multifaceted re-
lationship and to assess the benefits of routine anxiety as-
sessment in AF patients and the usefulness of anxiolytics and
antidepressants in the prevention and treatment of AF.
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